Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 6/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 4/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL17894392 | 0.89 | LTA4H (0.61) | LTA4HMEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL23902153 | 0.89 | F2 (0.65) | LTA4HMEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL4979973 | 0.87 | MEN1 (0.69) | LTA4HMEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL27683541 | 0.84 | PARP10 (0.57) | LTA4HMEN1KMT2ANPC1RAB9A | |
| SCHEMBL17894484 | 0.84 | MAOB (0.57) | LTA4HKMT2ANPC1RAB9AMRGPRX1 | |
| SCHEMBL3424405 | 0.84 | MEN1 (0.74) | LTA4HMEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL4598560 | 0.84 | LTA4H (0.75) | LTA4HMEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL4028152 | 0.83 | MAPK1 (0.58) | LTA4HMEN1KMT2A | |
| SCHEMBL17894553 | 0.83 | MAOB (0.61) | — | |
| SCHEMBL9725077 | 0.83 | MEN1 (0.72) | LTA4HMEN1KMT2ACYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342025-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS | THE UNIVERSITY OF BATH (GB) | 2017-11-30 | — | — | US | claimed |
| EP-3240775-A2 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS | Swansea University (GB) | 2017-11-08 | — | — | EP | claimed |
| WO-2016108045-A2 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS | SWANSEA UNIVERSITY (GB) | 2016-07-07 | — | — | WO | claimed |
| US-20170342025-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS | THE UNIVERSITY OF BATH (GB) | 2017-11-30 | — | — | US | disclosed |
| US-7351743-B1 | Therapeutic guanidines | WYETH (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070265348-A1 | N-(4-sec-butylphenyl)-N-benzylguanidine; modulate, particularly inhibit, the release of neurotransmitter such as glutamate; neurodegenerative disease: Parkinson's, Huntington's, Alzheimer's diseases, Amyotrophic Lateral Sclerosis, Down's Syndrome, epilepsy, atrophy, HIV | SCION PHARMACEUTICALS, INC, A DELAWARE CORPORATION | 2007-11-15 | — | — | US | disclosed |
| EP-0961618-B1 | 5-Pyrimidinyl-4-yl-Imidazole Derivate zur Behandlung von CSBP/RK/p38 vermittelten Erkrankungen | SMITHKLINE BEECHAM CORP (US) | 2004-08-04 | — | — | EP | disclosed |
| EP-0961618-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2002-07-17 | — | — | EP | disclosed |
| US-6369068-B1 | Amino substituted pyrimidine containing compounds | SMITHKLINE BEECHAM CORPORATION | 2002-04-09 | — | — | US | disclosed |
| US-6174924-B1 | Therapeutic guanidines | CAMBRIDGE NEUROSCIENCE, INC. | 2001-01-16 | — | — | US | disclosed |
| US-6153613-A | 2,3-diketopiperazine derivatives or their salts | TOYOMA CHEMICAL CO., LTD. (JP) | 2000-11-28 | — | — | US | disclosed |
| US-6143791-A | NERVOUS SYSTEM DISORDERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-11-07 | — | — | US | disclosed |
| EP-0961618-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-08 | — | — | EP | disclosed |
| EP-0918460-A1 | METHODS OF TREATMENT OF EYE TRAUMA AND DISORDERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-06-02 | — | — | EP | disclosed |
| US-5877174-A | ANTICOAGULANTS | TOYAMA CHEMICAL CO., LTD. (JP) | 1999-03-02 | — | — | US | disclosed |
| US-5869660-A | Process of preparing imidazole compounds | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-09 | — | — | US | disclosed |
| WO-1998025619-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-06-18 | — | — | WO | disclosed |
| US-5739143-A | Imidazole compounds and compositions | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-14 | — | — | US | disclosed |
| WO-1998004131-A1 | METHODS OF TREATMENT OF EYE TRAUMA AND DISORDERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1998-02-05 | — | — | WO | disclosed |
| EP-0805149-A1 | NOVEL 2,3-DIKETOPIPERAZINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 1997-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342025-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS | ZYX, MPO, CFB | LTA4H 360/4885MEN1 3309/4885KMT2A 4411/4885 |
| US-20070265348-A1 | N-(4-sec-butylphenyl)-N-benzylguanidine; modulate, particularly inhibit, the release of neurotransmitter such as glutamate; neurodegenerative disease: Parkinson's, Huntington's, Alzheimer's diseases, Amyotrophic Lateral Sclerosis, Down's Syndrome, epilepsy, atrophy, HIV | GAP43, NLN, HTT | LTA4H 2488/4885MEN1 3546/4885KMT2A 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.